Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
What to Expect Tell us where you are
Beyond FSP1 there are therapeutic opportunities across the CoQ 10 oxidoreductase network While FSP1 currently has the strongest targetability signal, other CoQ 10 oxidoreductases may be therapeutically leveraged in defined genetic, metabolic or tissue contexts: (1) DHODH axis (mitochondrial defense in select contexts): DHODH connects pyrimidine synthesis to mitochondrial CoQ reduction, and in some settings, DHODH inhibition has been proposed to heighten ferroptosis sensitivity, especially in GPX4-low states
It also reduces the intramitochondrial ratio of acetyl-CoA to free CoA, which in turn stimulates pyruvate dehydrogenase activity and promotes pyruvate oxidation
Patients who experience any suspected side effects should report them to the MHRA through the Yellow Card Scheme (yellowcard.mhra.gov.uk)
Evaluated transdermal delivery of copper tripeptide, demonstrating penetration through skin layers with potential for topical therapeutic applications
US$ 27.70
US$ 28.30
US$ 29.45
US$ 25.90
US$ 20.30
US$ 23.69
US$ 24.79
US$ 24.95
US$ 22.05
